Estimate survival in heart failure based on NYHA class, ejection fraction, comorbidities, and device therapy. Provides 1/3/5-year survival and median survival estimates.
The Heart Failure Life Expectancy Calculator provides estimated survival projections based on key prognostic factors in heart failure. While individual prognosis varies widely, this tool incorporates the most validated predictors: NYHA functional class, left ventricular ejection fraction, etiology, age, comorbidities (diabetes, CKD), natriuretic peptide levels, and device therapy.
Heart failure affects over 6 million Americans and 64 million people worldwide. Despite advances in medical therapy (neurohormonal blockade with ACEi/ARB/ARNI, beta-blockers, MRAs, SGLT2 inhibitors) and device therapy (ICD, CRT), heart failure carries significant mortality — approximately 50% 5-year mortality overall, comparable to many cancers.
This calculator provides individualized survival estimates to support goals-of-care conversations, device therapy discussions, advanced therapies (transplant, LVAD) referral timing, and patient education. Estimates should be discussed in the context of guideline-directed medical therapy (GDMT) optimization. Check the example with realistic values before reporting. Use the steps shown to verify rounding and units. Cross-check this output using a known reference case. Use the example pattern when troubleshooting unexpected results.
Prognostic awareness drives timely therapeutic escalation and advance care planning. Patients with a prognosis of <1 year median survival may benefit from palliative care referral and advance directive discussions. Those with moderate-risk profiles may benefit from device therapy evaluation. Accurate risk stratification also informs transplant candidacy and LVAD consideration.
Communicating prognosis is one of the most important and difficult tasks in heart failure management. This calculator provides a framework for these conversations.
Simplified prognostic model incorporating: Base mortality by NYHA class × Risk multipliers: - EF adjustment: <20% (×1.4), 20-29% (×1.15), ≥40% (×0.75) - Age adjustment: <50 (×0.7), 70-79 (×1.2), ≥80 (×1.5) - Diabetes (×1.25), CKD (×1.35), Ischemic (×1.1) - BNP thresholds: >1000 (×1.5), >500 (×1.2), <100 (×0.6) - Device benefit: ICD (-15%), CRT (-25%) Median survival = ln(0.5) / ln(1 - adjusted annual mortality)
Result: Median survival ~5.8 years, 5-year survival ~54%
A 65-year-old male with NYHA Class II, EF 30%, ischemic cardiomyopathy, ICD, and no major comorbidities has a moderate prognosis. GDMT optimization (ARNI, beta-blocker, MRA, SGLT2i) could further improve outcomes. CRT evaluation is warranted if QRS is wide with LBBB morphology.
Guideline-directed medical therapy (GDMT) has transformed HF prognosis. The four-drug combination for HFrEF (ARNI or ACEi, beta-blocker, MRA, SGLT2i) reduces cardiovascular death by approximately 50-60% compared to no neurohormonal blockade. Each drug class provides incremental survival benefit, and rapid initiation and up-titration are emphasized by current guidelines.
ICD for primary prevention is indicated in HFrEF (EF ≤35%) after ≥3 months of optimal medical therapy and life expectancy >1 year. CRT is indicated for EF ≤35% + QRS ≥150ms with LBBB + NYHA II-IV symptoms. CRT can improve EF by 5-15 points in responders (~65% response rate) and reduce mortality by ~25%. Patient selection using ECG criteria and imaging is critical.
The Seattle Heart Failure Model (SHFM) predicts 1/2/3-year survival using ~20 variables including medications and devices. The MAGGIC score uses 13 clinical variables. Both are validated but have limitations in contemporary populations treated with SGLT2i and ARNI. Machine learning models are being developed to improve prediction accuracy using EHR data.
Individual predictions have substantial uncertainty. Models like the Seattle Heart Failure Model (SHFM) and MAGGIC score have c-statistics of 0.72-0.80, meaning they discriminate reasonably but cannot predict an individual’s exact outcome. Estimates should be communicated as ranges, not precise numbers.
Yes. GDMT optimization can dramatically change prognosis. ARNI (sacubitril/valsartan) reduces mortality by 20% vs ACEi. SGLT2 inhibitors reduce mortality by 13-17%. CRT improves EF and survival in selected patients. Some patients with newly diagnosed HF who respond to therapy can have near-normal EF recovery and prognosis.
Advanced heart failure therapy evaluation should begin when patients have persistent NYHA III-IV symptoms despite maximally tolerated GDMT, declining renal function, recurrent hospitalizations, inotrope dependence, or peak VO₂ <14 mL/kg/min. Estimated survival <2 years without advanced therapy is a common referral trigger.
Palliative care should be integrated early, not just at end of life. HF palliative care addresses symptom management, advance care planning, caregiver support, and navigation of complex treatment decisions. Studies show palliative care integration improves quality of life without reducing survival.
HFpEF (EF ≥50%) has comparable overall mortality to HFrEF (EF <40%), though the trajectory differs. HFpEF patients are more likely to die from non-cardiovascular causes (cancer, infection) and have fewer disease-modifying therapies. SGLT2 inhibitors are the first class to improve outcomes in HFpEF.
Both matter. Absolute BNP >1000 pg/mL indicates high risk. However, a rising BNP trajectory despite therapy is more prognostically significant than a stable level. A >30% decrease in BNP with treatment predicts improved outcomes. Target-guided BNP therapy has shown benefit in some trials.